Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

奥马佐单抗 医学 哮喘 恶化 安慰剂 人口 不利影响 儿科 内科学 入射(几何) 随机对照试验 哮喘恶化 重症监护医学 免疫球蛋白E 免疫学 替代医学 抗体 病理 环境卫生 物理 光学
作者
Marc J.C. Humbert,Richard W. Beasley,Jon G. Ayres,Raymond G. Slavin,J. Hébert,Jean J. Bousquet,K.M. Beeh,S. Ramos,Giorgio Walter Canonica,Simon Hedgecock,H. Fox,Martin Blogg,Karen Surrey
出处
期刊:Allergy [Wiley]
卷期号:60 (3): 309-316 被引量:1204
标识
DOI:10.1111/j.1398-9995.2004.00772.x
摘要

BACKGROUND: Patients with severe persistent asthma who are inadequately controlled despite Global Initiative for Asthma (GINA) 2002 step 4 therapy are a challenging population with significant unmet medical need. We determined the effect of omalizumab on clinically significant asthma exacerbations (requiring systemic corticosteroids) in the first omalizumab study to exclusively enrol patients from this difficult-to-treat patient population. METHODS: Following a run-in phase, patients (12-75 years) inadequately controlled despite therapy with high-dose inhaled corticosteroids (ICS) and long-acting beta(2)-agonists (LABA) with reduced lung function and a recent history of clinically significant exacerbations were randomized to receive omalizumab or placebo for 28 weeks in a double-blind, parallel-group, multicentre study. RESULTS: A total of 419 patients were included in the efficacy analyses. The clinically significant asthma exacerbation rate (primary efficacy variable), adjusted for an observed relevant imbalance in history of clinically significant asthma exacerbations, was 0.68 with omalizumab and 0.91 with placebo (26% reduction) during the 28-week treatment phase (P = 0.042). Without adjustment, a similar magnitude of effect was seen (19% reduction), but this did not reach statistical significance. Omalizumab significantly reduced severe asthma exacerbation rate (0.24 vs 0.48, P = 0.002) and emergency visit rate (0.24 vs 0.43, P = 0.038). Omalizumab significantly improved asthma-related quality of life, morning peak expiratory flow and asthma symptom scores. The incidence of adverse events was similar between treatment groups. CONCLUSIONS: In patients with inadequately controlled severe persistent asthma, despite high-dose ICS and LABA therapy, and often additional therapy, omalizumab significantly reduced the rate of clinically significant asthma exacerbations, severe exacerbations and emergency visits. Omalizumab is effective and should be considered as add-on therapy for patients with inadequately controlled severe persistent asthma who have a significant unmet need despite best available therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
ptyz霍建华完成签到 ,获得积分10
2秒前
激动的海豚完成签到,获得积分10
2秒前
cdercder的应助被皮卡丘采纳,获得10
2秒前
wang发布了新的文献求助10
3秒前
直率翠绿完成签到,获得积分10
4秒前
xx发布了新的文献求助10
4秒前
洛泱完成签到 ,获得积分10
4秒前
5秒前
跳跃的岂愈完成签到,获得积分10
6秒前
畅快的静蕾完成签到,获得积分10
6秒前
7秒前
7秒前
7秒前
CipherSage的应助被冷静夜蕾采纳,获得10
7秒前
丘比特的应助被Han采纳,获得10
7秒前
8秒前
cookieee214完成签到 ,获得积分10
10秒前
香蕉觅云的应助被科研通管家采纳,获得10
10秒前
Nole的应助被科研通管家采纳,获得10
10秒前
丘比特的应助被科研通管家采纳,获得10
11秒前
TFauthor发布了新的文献求助10
11秒前
wanci的应助被科研通管家采纳,获得10
11秒前
科研通AI65的应助被科研通管家采纳,获得10
11秒前
香蕉觅云的应助被科研通管家采纳,获得10
11秒前
Hello的应助被科研通管家采纳,获得10
11秒前
大模型的应助被科研通管家采纳,获得10
11秒前
共享精神的应助被科研通管家采纳,获得10
11秒前
情怀的应助被科研通管家采纳,获得10
11秒前
斯文败类的应助被科研通管家采纳,获得10
12秒前
CipherSage的应助被科研通管家采纳,获得10
12秒前
秋风的应助被科研通管家采纳,获得10
12秒前
FashionBoy的应助被科研通管家采纳,获得10
12秒前
hotofei完成签到,获得积分10
12秒前
bkagyin的应助被科研通管家采纳,获得10
12秒前
LKK完成签到 ,获得积分10
12秒前
Nole的应助被科研通管家采纳,获得10
12秒前
12秒前
ding的应助被科研通管家采纳,获得10
12秒前
NexusExplorer的应助被科研通管家采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188221
求助须知:如何正确求助?哪些是违规求助? 9576025
关于积分的说明 21845049
捐赠科研通 7786165
什么是DOI,文献DOI怎么找? 3435226
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482157